# A Study of Amivantamab and Lazertinib in People With Non-Small Cell Lung Cancer (NSCLC)

> **NCT04965090** · PHASE2 · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 43 (actual)

## Conditions studied

- Metastatic Non Small Cell Lung Cancer
- Recurrent Non Small Cell Lung Cancer

## Interventions

- **DRUG:** Amivantamab
- **DRUG:** Lazertinib

## Key facts

- **NCT ID:** NCT04965090
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-09-30
- **Primary completion:** 2025-12-15
- **Final completion:** 2025-12-15
- **Target enrollment:** 43 (ACTUAL)
- **Last updated:** 2025-12-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04965090

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04965090, "A Study of Amivantamab and Lazertinib in People With Non-Small Cell Lung Cancer (NSCLC)". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT04965090. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*